Old drugs get new rebate breaks—at Medicare's expense

What it does

This bill creates a fast-track designation process for old drugs being studied for new medical uses. If a drug has been on the market for at least 10 years and a manufacturer is testing it for a new indication that addresses an unmet medical need affecting a large share of Medicare/Medicaid beneficiaries, the drug can be designated a 'priority research drug.' Once designated, these drugs are excluded from being treated as 'line extensions' of the original drug for purposes of calculating manufacturer rebates under Medicare and Medicaid, potentially lowering the rebates owed and increasing the drug's profitability.

Why we flagged it

The bill's operative mechanism is a narrow financial exemption for a specific class of drugs (old drugs being studied for new uses) from rebate calculations. The public-health framing (incentivizing research into unmet medical needs) masks a direct reduction in the rebates manufacturers must pay to government health programs.

What the text implies

• The 'high prevalence' threshold (33% of claims from federal programs) is low enough that many common chronic diseases in elderly/low-income populations would qualify, potentially opening the exemption to a broad class of drugs.
• The bill does not require the manufacturer to demonstrate that the rebate reduction is necessary to fund the research; it is a blanket exemption tied only to the drug's age and the indication's prevalence.
• Once a drug is designated, it remains exempt from line-extension rebate rules for the duration of the investigation, with no sunset or performance requirement tied to research success.
• The 60-day designation window is automatic ('shall designate') if criteria are met, removing discretion and creating a predictable pathway for manufacturers to reduce rebate obligations.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill reduces rebate obligations for manufacturers of repurposed drugs, shifting costs to Medicare and Medicaid programs and ultimately to taxpayers and beneficiaries through higher net drug prices. While the bill frames this as incentivizing research into new uses for old drugs, the financial benefit flows to manufacturers, not to patients or the public health system.

Who stands to gain

• pharmaceutical manufacturers with drugs approved 10+ years ago
• companies conducting clinical trials on old drugs for new indications

Named in the bill

Secretary of Health and Human Services, Medicare (Title XVIII), Medicaid (Title XIX), Federal Food, Drug, and Cosmetic Act (Section 505), Public Health Service Act (Section 351), 340B Drug Discount Program, Department of Veterans Affairs

Where it stands

1 cosponsor: 1 Republicans.

• Apr 1, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 1, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $60,000 in lobbying spend. A filing names 1 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Donald Davis, the sponsor, reported $1,617,446 in PAC receipts in the 2026 cycle.

• Bausch Health — $60,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.